Advertisement

Topics

Luminex Corporation Reports Second Quarter 2017 Financial Results

12:24 EDT 7 Aug 2017 | PR Newswire

AUSTIN, Texas, Aug. 7, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the second quarter of 2017.  Financial and operating highlights for the quarter include the following:

  • Consolidated revenue of $76.5 million, an increase of 19% compared to the second quarter 2016. 
  • Total automated sample to answer molecular product revenue of $10.7 million; pro-forma growth of 44% compared to $7.4 million in the second quarter of 2016.
  • 270 multiplexing analyzers were shipped during the quarter; included in this figure is a combination of MAGPIX® systems, LX systems, FLEXMAP 3D® systems.
  • Corporate gross margin decreased to 65% from 68% in the first quarter, 2017, primarily due to an anticipated shift in overall product mix.
  • GAAP net income of $5.5 million, or $0.13 per diluted share.  Non-GAAP net income of $11.2 million, or $0.26 per diluted share (see Non-GAAP reconciliation).
  • Received FDA clearance of the ARIES® Bordetella assay and CE-IVD mark for the ARIES® Norovirus assay. In July, Luminex received FDA clearance of and CE-IVD mark for the ARIES® C.Difficile assay.
  • Gained reimbursement approval in Japan for the VERIGENE® gram positive and gram negative blood culture assays.

"I am very pleased with the Company's performance year-to-date and we remain focused on delivering double digit revenue growth and increased shareholder value. In addition, I'm happy to announce, that only a year after its acquisition, Nanosphere was accretive to the Company's operating results in the second quarter," said Homi Shamir, President and Chief Executive Officer of Luminex.  "The combination of the ARIES and VERIGENE sample-to-answer systems coupled with our non-automated solutions has provided our customers with a technology portfolio that addresses their needs.  Further, the full integration of our sales force helped drive our execution in the second quarter."

"Looking forward, we believe that our diversified business model offers multiple, significant growth opportunities as we aggressively expand the test menu on these platforms.  With multiple clearances in the second quarter and the ARIES C.Diff assay approval in July, Luminex now has ten FDA-cleared assays that run on our automated sample-to-answer molecular systems."

REVENUE SUMMARY(in thousands, except percentages) 

Three Months Ended

June 30,

Variance

2017

2016

($)

(%)

(unaudited)

System sales

$             9,905

$             8,993

$          912

10%

Consumable sales

13,310

13,334

(24)

0%

Royalty revenue

10,813

11,352

(539)

-5%

Assay revenue

37,753

25,885

11,868

46%

Service revenue

2,795

2,547

248

10%

Other revenue

1,881

2,055

(174)

-8%

$           76,457

$           64,166

$     12,291

19%

FINANCIAL OUTLOOK AND GUIDANCE

The Company provides annual revenue guidance, updated, as appropriate, at each quarterly reporting period. Luminex reiterates its 2017 annual revenue guidance range to between $300 million and $310 million. The company expects third quarter 2017 revenue to be between $73 million and $75 million.

CONFERENCE CALL

Management will host a conference call at 3:30 p.m. CDT / 4:30 p.m. EDT, Monday, August 7, 2017 to discuss the operating highlights and financial results for the second quarter 2017 ended June 30, 2017. The conference call will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the 'replay' link.

Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at http://www.luminexcorp.com.

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding expected revenue and cost savings, projected 2017 performance, including revenue guidance, including the revenue contribution from our recently completed acquisition of Nanosphere, Inc. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products and technology in development, including ARIES®, Verigene® and NxTAG® products; dependence on strategic partners for development, commercialization and distribution of products; concentration of Luminex's revenue in a limited number of direct customers and strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating Luminex's technology; budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of material resource planning challenges; the timing of and process for regulatory approvals; the impact of the ongoing uncertainty in global finance markets and changes in governmental funding, including its effects on the capital spending policies of Luminex's partners and end users and their ability to finance purchases of Luminex's products; fluctuations in quarterly results due to a lengthy and unpredictable sales cycle; fluctuations in bulk purchases of consumables; fluctuations in product mix, and the seasonal nature of some of Luminex's assay products; Luminex's ability to obtain and enforce intellectual property protections on Luminex's products and technologies; risks and uncertainties associated with implementing Luminex's acquisition strategy, including Luminex's ability to obtain financing; Luminex's ability to integrate acquired companies or selected assets into Luminex's consolidated business operations, and the ability to recognize the benefits of Luminex's acquisitions; reliance on third party distributors for distribution of specific Luminex-developed and manufactured assay products; Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels; changes in principal members of Luminex's management staff; potential shortages, or increases in costs, of components or other disruptions to Luminex's manufacturing operations; competition and competitive technologies utilized by Luminex's competitors; Luminex's ability to successfully launch new products in a timely manner; Luminex's increasing dependency on information technology to improve the effectiveness of Luminex's operations and to monitor financial accuracy and efficiency; the implementation, including any modification, of Luminex's strategic operating plans; the uncertainty regarding the outcome or expense of any litigation brought against or initiated by Luminex, risks relating to Luminex's foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost effective and timely manner; difficulties in accounts receivable collections; the burden of monitoring and complying with foreign and international laws and treaties; and the burden of complying with and change in international taxation policies, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2017 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

LUMINEX CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

June 30,

December 31,

2017

2016

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$     103,705

$        93,452

Accounts receivable, net

33,133

32,365

Inventories, net

47,095

40,775

Prepaids and other

8,208

7,145

Total current assets

192,141

173,737

Property and equipment, net

57,890

57,375

Intangible assets, net

80,318

84,841

Deferred income taxes

35,511

42,497

Goodwill

85,481

85,481

Other

7,611

6,785

Total assets

$     458,952

$      450,716

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable

$       10,456

$        12,276

Accrued liabilities

18,327

22,804

Deferred revenue

4,933

5,120

Total current liabilities

33,716

40,200

Deferred revenue

1,720

1,875

Other

4,929

4,962

Total liabilities

40,365

47,037

Stockholders' equity:

Common stock

43

43

Additional paid-in capital

341,290

336,430

Accumulated other comprehensive loss

(1,090)

(1,692)

Retained earnings

78,344

68,898

Total stockholders' equity

418,587

403,679

Total liabilities and stockholders' equity

$     458,952

$      450,716

LUMINEX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three Months Ended

Six Months Ended

June 30,

June 30,

2017

2016

2017

2016

(unaudited)

(unaudited)

Revenue

$  76,457

$  64,166

$   154,236

$  127,147

Cost of revenue

26,396

19,245

51,389

37,420

Gross profit

50,061

44,921

102,847

89,727

Operating expenses:

Research and development

12,260

11,543

24,680

22,562

Selling, general and administrative

28,153

24,190

52,150

44,549

Amortization of acquired intangible assets

2,166

1,688

4,523

3,315

Total operating expenses

42,579

37,421

81,353

70,426

Income from operations

7,482

7,500

21,494

19,301

Other income, net

1

(1,446)

(5)

(1,425)

Income before income taxes

7,483

6,054

21,489

17,876

Income tax expense

(1,939)

(401)

(6,714)

(3,453)

Net income

$    5,544

$    5,653

$     14,775

$    14,423

Net income attributable to common stock holders

Basic

$    5,441

$    5,653

$     14,499

$    14,423

Diluted

$    5,441

$    5,653

$     14,499

$    14,423

Net income per share attributable to common stock holders

Basic

$      0.13

$      0.13

$         0.34

$        0.34

Diluted

$      0.13

$      0.13

$         0.34

$        0.34

Weighted-average shares used in computing net income per share

Basic

43,160

42,534

43,030

42,440

Diluted

43,259

42,575

43,128

42,440

Dividends declared per share

$      0.06

-

$         0.12

-

LUMINEX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Three Months Ended

Six Months Ended

June 30,

June 30,

2017

2016

2017

2016

(unaudited)

(unaudited)

Cash flows from operating activities:

Net income

$     5,544

$   5,653

$     14,775

$   14,423

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

5,651

4,276

11,270

8,488

Stock-based compensation

4,026

3,475

4,748

4,655

Deferred income tax expense

4,332

(395)

7,267

2,931

Loss (gain) on sale or disposal of assets

-

4

-

41

Other

478

(17)

922

(71)

Changes in operating assets and liabilities:

Accounts receivable, net

3,911

7,221

(758)

6,673

Inventories, net

(3,417)

(4,142)

(6,304)

(4,040)

Other assets

(1,892)

508

(1,197)

672

Accounts payable

1,337

3,737

(2,369)

2,724

Accrued liabilities

2,661

1,098

(7,411)

(6,174)

Deferred revenue

(547)

(209)

(350)

621

Net cash provided by operating activities

22,084

21,209

20,593

30,943

Cash flows from investing activities:

Sales and maturities of available-for-sale securities

-

19,491

-

19,491

Purchase of property and equipment

(2,970)

(2,871)

(6,403)

(5,719)

Proceeds from sale of assets

-

3

-

3

Business acquisition consideration, net of cash acquired

-

(66,902)

-

(66,902)

Purchase of cost method investment

(500)

-

(1,000)

-

Acquired technology rights

-

-

-

(200)

Net cash used in investing activities

(3,470)

(50,279)

(7,403)

(53,327)

Cash flows from financing activities:

Payments on debt

-

(25,000)

-

(25,000)

Proceeds from issuance of common stock

1,495

1,406

2,229

1,762

Shares surrendered for tax withholding

(40)

(35)

(2,096)

(1,484)

Dividends

(2,636)

(2,636)

Net cash provided by (used in) financing activities

(1,181)

(23,629)

(2,503)

(24,722)

Effect of foreign currency exchange rate on cash

(194)

115

(434)

278

Change in cash and cash equivalents

17,239

(52,584)

10,253

(46,828)

Cash and cash equivalents, beginning of period

86,466

134,302

93,452

128,546

Cash and cash equivalents, end of period

$ 103,705

$ 81,718

$   103,705

$   81,718

LUMINEX CORPORATION

NON-GAAP RECONCILIATION

(in thousands)

Three Months Ended

Six Months Ended

June 30,

June 30,

2017

2016

2017

2016

(unaudited)

(unaudited)

Income from operations

$   7,482

$   7,500

$   21,494

$  19,301

Stock-based compensation

4,026

3,475

4,748

4,655

Amortization of acquired intangible assets

2,166

1,688

4,523

3,315

Acquisition costs

-

2,008

-

2,008

Severance costs

559

160

658

814

Adjusted income from operations

$ 14,233

$ 14,831

$   31,423

$  30,093

Other income, net

1

(1,446)

(5)

(1,425)

Acquisition costs

-

1,500

-

1,500

Income tax expense

(1,939)

(401)

(6,714)

(3,453)

Income tax effect of above adjusting items

(1,112)

(363)

(1,292)

(416)

Adjusted net income

$ 11,183

$ 14,121

$   23,412

$  26,299

Adjusted net income per share, basic

$     0.26

$     0.33

$       0.54

$      0.62

Shares used in computing adjusted net income per share, basic

43,160

42,534

43,030

42,440

Adjusted net income per share, diluted

$     0.26

$     0.33

$       0.54

$      0.62

Shares used in computing adjusted net income per share, diluted

43,259

42,575

43,128

42,440

The Company makes reference in this release to "non-GAAP net income" which excludes stock-based compensation expense, amortization of acquired intangible assets and the impact of costs associated with legal proceedings; which are unpredictable and can vary significantly from period to period; and certain other recurring and non-recurring expenses. The Company believes that excluding these items and their related tax effects from its financial results reflects operating results that are more indicative of the Company's ongoing operating performance while improving comparability to prior periods, and, as such may provide investors with an enhanced understanding of the Company's past financial performance and prospects for the future. In addition, the Company's management uses such non-GAAP measures internally to evaluate and assess its core operations and to make ongoing operating decisions. This information is not intended to be considered in isolation or as a substitute for income from operations, net income, net income per share or expense information prepared in accordance with GAAP.

Contacts:

Harriss T. Currie

Matthew Scalo

Sr. Vice President, Finance and Chief Financial Officer

Sr. Director, Investor Relations

512-219-8020

512-219-8020

hcurrie@luminexcorp.com

mscalo@luminexcorp.com

View original content:http://www.prnewswire.com/news-releases/luminex-corporation-reports-second-quarter-2017-financial-results-300500415.html

SOURCE Luminex Corporation

NEXT ARTICLE

More From BioPortfolio on "Luminex Corporation Reports Second Quarter 2017 Financial Results"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Assays
An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...